Objective: Based on the assumption that normal TSH concentration rules out the presence of autonomous functioning thyroid nodules (AFTNs), clinical guidelines on the management of thyroid nodules only recommend a thyroid scan if TSH concentration is subnormal. However, the proportion of AFTN presenting with a normal TSH is unknown. Our objective is therefore to determine the proportion of AFTNs with a normal TSH level to ascertain whether a normal TSH really rules out an AFTN. Design: Retrospective study on 368 patients with an AFTN. Methods: Thyroid scans with a diagnosis of AFTN were reviewed retrospectively by one of us (R Moreno-Reyes), blinded to the clinical data. The diagnosis of solitary AFTN was confirmed in 368 patients. Among them, we selected 217 patients based on the absence of another thyroid nodule O10 mm, the absence of medical conditions able to interfere with thyroid function, and the completeness of the data. Results: The proportion of AFTNs with normal TSH was 49%. This proportion increased to 71% in patients for whom thyroid scan was performed in the workup of a thyroid nodule. Conclusions: Our data suggest that serum TSH is not an effective screening tool to diagnose AFTNs. Using 'TSH-only' screening, as recommended by the majority of guidelines, the diagnosis of AFTN would have been missed in 71% of our patients in the workup of a thyroid nodule. Thyroid scan remains the gold standard for detecting AFTN and should be considered before performing fine-needle aspiration cytology (FNAC), as the reliability of FNAC in an unsuspected AFTN remains unclear.
Introduction
Management of thyroid nodules is a very common problem in adults (1) . Thyroid scan is the only technique that permits evaluation of the functional characteristics of a nodule. The vast majority of nodules are hypofunctioning but a minority are hyperfunctioning, autonomously functioning thyroid nodules (AFTNs). AFTNs account for 5-10% of palpable nodules (2, 3) . Thyroid scan is now rarely used in the management of thyroid nodules based on the assumption that thyroid-stimulating hormone (TSH) levels are always subnormal in the presence of an There is a general agreement between all the guidelines that a thyroid scan should be performed in the presence of subnormal TSH, but which patients, if any, with a thyroid nodule and a normal TSH deserve a thyroid scan remains an area of disagreement (10) . AACE, BTA, ATA, and SFE guidelines recommend thyroid scan only when the level of TSH is subnormal or 'close to the lower limit of normal', but only AAE recommends considering thyroid scan in iodine-deficient areas even if the TSH level is in the normal range, particularly in the presence of a multinodular goiter. However, this assertion comes from small clinical studies (11) or expert opinions (12) . All groups agree that AFTNs with a low TSH level do not necessitate FNAC, based on the very low risk of cancer in a hyperfunctioning thyroid nodule. The extension of this statement to AFTN with a normal TSH level is an area of disagreement but is proposed by some authors (10) . In addition, FNAC of AFTNs is associated with a risk of equivocal results (follicular neoplasm) (13) . Therefore, in the absence of a thyroid scan in the workup of a patient with a thyroid nodule and a normal TSH level, there is a risk of proposing FNAC in an unsuspected AFTN. However, the proportion of patients with an AFTN presenting with a normal TSH level is unknown. Historical series suggested that thyrotoxicosis was rare below a diameter of 2.5 cm and that the percentage of toxicity reaches only 30-40% between 3 and 4.5 cm (14, 15) . Since in our institution thyroid scan is still systematically performed in the workup of thyroid nodule and hyperthyroidism, we undertook a retrospective study aiming to analyze the relationship between nodule size and thyroid function and thus evaluate the proportion of AFTNs with a normal TSH level.
Subjects and methods

Subjects
Between 1993 and 2012, 11 192 thyroid scans were performed in adult patients in our department of nuclear medicine. Among them, we found 466 patients with an output describing a solitary AFTN. All the thyroid scans were reviewed by one of us (R Moreno-Reyes) blinded to the clinical data. The study flow diagram is presented in Fig. 1 . We included only patients with a certain AFTN diagnosed based on the thyroid scan using 
Assay
The normal reference intervals for TSH remained unchanged at between 0.4 and 4 mU/ml over the period of the study. From 1993 to 06/1998, TSH was measured using a Chiren Diagnostics ACS:180 Plus automated chemiluminescence immunoassay analyzer (Ciba Corning Diagnostics Corp., Medfield, MA, USA); from 07/1998 until now by electrochemiluminescence, initially to 10/2002 using an Elecsys (Roche-Boehringer); and from 11/2002 until now using a module E170 (Roche Diagnostics).
Analysis of the clinical data
Each patient undergoing thyroid scan was examined by the physician working in the department of Nuclear Medicine who summarizes the clinical data. We used this summary to identify the reason for performing the thyroid scan. Other clinical data were found in the medical file of the patient and used to determine the first time point at which all the data were available. Therefore, in some patients, age at analysis may differ from age at diagnosis.
Statistical analysis
Statistical analyses were performed using Prism 5 (GraphPad Software, San Diego, CA, USA 
Ethical approval
This study was approved by the ethics board at the Hôpital Erasme (P2011/063).
Results
Age and sex distribution
Among the 368 patients with AFTN, the female-to-male ratio was 2.9 (Table 1) . We had no reliable data on age at diagnosis for five patients. Female patients were significantly younger at diagnosis than men. Male patients were rare below 40 years and the sex ratio F:M decreased abruptly with age from w18 below 40 years to w2.0 above 50 years (P!0.01) (Fig. 2) .
Circumstances of diagnosis
No reliable data on the circumstances of diagnosis were available for 41 patients (32 females and nine males). Data were therefore analysed for 327 patients. AFTN was more frequently diagnosed in the workup of thyroid nodules in females and in the workup of thyroid dysfunction in males (P!0.01) ( Table 1) . Patients with AFTN discovered in the workup of a thyroid nodule were significantly younger than those whose AFTN was discovered in the workup of thyroid dysfunction (P!0.01 in females and males).
AFTN size and distribution
AFTN was located in the isthmus in 15 patients, but more frequently in the right lobe (221 patients) than in the left lobe (132 patients) (P!0.01). For the calculation of the size of AFTNs, we excluded those !10 mm and those for which we had no reliable US data. Data on the mean size of AFTNs at the time of analysis were therefore available for 314 patients. The mean size was 28.0G0.7 mm, with no differences between males (29.5G1.2 mm) and females (27.5G0.8 mm).
Thyroid function
We excluded all patients with the conditions that may interfere with thyroid function or with other nodules O1 cm. The analysis of the relationship between AFTN size and thyroid function was carried out only in Group III when all reliable data were available for the first time. This explains why age at analysis (53.9G1.0) differs slightly from age at diagnosis (53.0G1.0). In Group III (Table 2) , TSH levels !0.4 mU/ml were observed in 110 of 217 patients (50.7%): 77 females and 33 males (sex ratio 2.33), and R0.4 mU/ml in 107 patients (49.3%): 83 females and 24 males (sex ratio 3.46). As expected, the main diameter and the volume of the nodule were greater in the subgroup with a TSH level !0.4 mU/ml. To address more precisely the question of the sensitivity of a subnormal TSH level in the detection of an AFTN during the workup of a thyroid nodule, in Fig. 3 , we compare results obtained for the whole population (Group III (nZ217)) and results obtained for patients for whom the diagnosis of AFTN was made during the workup of a thyroid nodule (nZ122).
In the whole population, normal TSH was observed in 49% of AFTNs. This proportion increased to 71% in the subpopulation where AFTN was discovered in the workup of a thyroid nodule (Fig. 3a) . The relationship between the size of the nodule (main diameter or volume) and the persistence of a normal TSH level in the whole population and in the subpopulation where AFTN was discovered in the workup of a thyroid nodule is shown in Fig. 3b and c. We observed a decrease in the proportion of AFTNs with a normal TSH level with increase in size of the nodule, but in the workup of a thyroid nodule, the majority of patients with AFTNs maintained a TSH R0.4 mU/ml for a maximal diameter up to 40 mm or a volume up to 10 ml. In the 
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www.eje-online.org global population of AFTN, the median serum TSH was 0.38 and 0.80 mU/ml when AFTN was discovered in the workup of thyroid nodule. As shown in Table 3 , median values decrease with the size of the nodule (P!0.01), but it was not possible do determine a threshold above which an AFTN was unlikely. Whatever the size of the nodule is the 75th and 90th percentiles remain clearly in the normal range, particularly when AFTN was discovered in the workup of a thyroid nodule. This confirms that even a 'low normal' TSH value does not permit diagnosis of AFTN.
Discussion
The present study is a retrospective study carried out using clinical data of 368 patients with an AFTN. Our data indicate that serum TSH measurement is not an effective screening test to diagnose an AFTN because 71% of the patients included in our study for the assessment of a thyroid nodule had a normal TSH value.
As has been observed already in previous series, a higher prevalence of AFTN is observed in women, but less so than previously reported (14, 15, 16) . However, our study allowed collection of new and interesting data: the age at which a nodule comes to clinical attention is lower in females than in males and the sex ratio F:M progressively decreases with age from 18 below 40 years to w2 above 50 years, suggesting a role of estrogens in the occurrence and growth of hot nodules, as has been suggested more generally for thyroid tumors (17) . Another interesting finding is the fact that, even if the size of the nodule is similar in males and females, most AFTNs were diagnosed in the workup of thyroid nodule in females and in the workup of thyroid dysfunction in males. Age at diagnosis was higher when an AFTN was diagnosed in the workup of thyroid dysfunction. This could be a recruitment bias due to the more frequent use of routine blood analysis in elderly patients and therefore the diagnosis of asymptomatic hyperthyroidism.
In the second part of the study, we analysed the relationship between the size of the autonomous nodules, evaluated by US, and thyroid function in 217 patients with a solitary AFTN. If we considered this population as a whole, 49% of those patients had a TSH level R0.4 mU/ml. If we analysed only patients for whom the scan had been performed in the workup of a thyroid nodule, this proportion increases to 71%. This proportion was not related to gender or age, but was inversely related to the size of the nodule. However, some patients are hyperthyroid for a nodule with a diameter !2 cm and some are not for nodule with a diameter O5 cm. Gain-of-function mutations of the TSHR or GNAS are the main cause of AFTN. More than 40 TSHR mutations have been reported, but the correlation between the in vitro activity of a mutated receptor and the clinical phenotype is weak (18) . Therefore, the heterogeneity in clinical behaviour of AFTN is probably not caused by differences in causal TSHR mutations. This heterogeneity may instead reflect the heterogeneity of cellular density from one nodule to another due to various decreases in colloid space, the difficulty of estimating the actual weight of the active nodule (19) or the presence of an impaired iodide organification as observed in 60% of AFTNs (20) . Similar to several other countries, Belgium is an area with mild iodine deficiency (21, 22) , and the goitrogenic role of pregnancy is observed only in iodine-deficient areas (23) . Therefore, we cannot claim that our observation is valid for patients from areas with optimal iodine intake. However, the only study that compared thyroid function in patients with AFTN from iodine-deficient or -sufficient areas reported no differences in the proportion of patients with hyperthyroidism (14) . On the basis of 'TSH-only' screening, 71% of the patients included in our study for the assessment of a thyroid nodule would have undergone a FNAC within an AFTN with undetermined proportion of false-positive suspicious results. Even if the benign nature of the nodule is confirmed, follow-up will be different for an AFTN because it will mainly consist of detection and adequate treatment of thyroid dysfunction. To evaluate the most appropriate strategy, the risk of obtaining an equivocal result in FNAC of an AFTN should be quantified in a prospective study as well as the risk of cancer in an AFTN patient with a low or a normal TSH level.
Strengths and limitations of the study
Our study is one of the largest studies on AFTNs with reliable clinical data, sensitive TSH measurement, and using US to evaluate more accurately the size of the nodule and identify patients with multinodular disease. One limitation of our study is the use of 99m TcO4 K to detect AFTN. Some nodules may appear 'hot' on 99m
TcO4
K and cold on 123-I. This discordance is observed in only 5% of patients and therefore could not explain our results (24) . In the same way, thyroid hormone suppression tests were not done; therefore, we cannot exclude the possibility that some nodules with increased 99m technetium uptake are not autonomously functioning. The fact that our study is a retrospective study is an important limitation because only AFTNs that came to clinical attention were selected. However, the generalized use of thyroid scan in our institution for patients with thyroid nodules as well as for patients with hyperthyroidism limits the risk of systematic bias.
Conclusion
TSH measurement is not an effective test to detect the presence of an AFTN in the workup of a thyroid nodule. Thyroid scan still has a role in the workup of a thyroid nodule, because it remains the only technique that permits the diagnosis of an AFTN, a diagnosis accounting for 5-10% of palpable nodules, which do probably not require further investigation.
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